Form 8-K - Current report:
SEC Accession No. 0000950170-23-050039
Filing Date
2023-09-27
Accepted
2023-09-27 07:05:08
Documents
13
Period of Report
2023-09-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20230927.htm   iXBRL 8-K 49281
2 EX-99.1 ubx-ex99_1.htm EX-99.1 22998
  Complete submission text file 0000950170-23-050039.txt   194949

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ubx-20230927_pre.xml EX-101.PRE 9851
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ubx-20230927.xsd EX-101.SCH 2484
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ubx-20230927_lab.xml EX-101.LAB 13350
7 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20230927_htm.xml XML 4715
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 231281797
SIC: 2834 Pharmaceutical Preparations